Metformin Use Is Associated With Reduced Mortality in a Diverse Population With COVID-19 and Diabetes
Andrew B Crouse, Tiffany Grimes, Peng Li, Matthew Might, Fernando Ovalle, Anath Shalev
Frontiers in Endocrinology, doi:10.3389/fendo.2020.600439
Background: Coronavirus disease-2019 (COVID-19) is a growing pandemic with an increasing death toll that has been linked to various comorbidities as well as racial disparity. However, the specific characteristics of these at-risk populations are still not known and approaches to lower mortality are lacking.
Methods: We conducted a retrospective electronic health record data analysis of 25,326 subjects tested for COVID-19 between 2/25/20 and 6/22/20 at the University of Alabama at Birmingham Hospital, a tertiary health care center in the racially diverse Southern U.S. The primary outcome was mortality in COVID-19-positive subjects and the association with subject characteristics and comorbidities was analyzed using simple and multiple linear logistic regression.
Results: The odds ratio of contracting COVID-19 was disproportionately high in Blacks/ African-Americans (OR 2.6; 95% CI 2.19-3.10; p<0.0001) and in subjects with obesity (OR 1.93; 95% CI 1.64-2.28; p<0.0001), hypertension (OR 2.46; 95% CI 2.07-2.93; p<0.0001), and diabetes (OR 2.11; 95% CI 1.78-2.48; p<0.0001). Diabetes was also associated with a dramatic increase in mortality (OR 3.62; 95% CI 2.11-6.2; p<0.0001) and emerged as an independent risk factor in this diverse population even after correcting for age, race, sex, obesity, and hypertension. Interestingly, we found that metformin treatment prior to diagnosis of COVID-19 was independently associated with a significant reduction in mortality in subjects with diabetes and COVID-19 (OR 0.33; 95% CI 0.13-0.84; p=0.0210).
Conclusion: Thus, these results suggest that while diabetes is an independent risk factor for COVID-19-related mortality, this risk is dramatically reduced in subjects taking metformin prior to diagnosis of COVID-19, raising the possibility that metformin may provide a protective approach in this high risk population.
ETHICS STATEMENT The studies involving human participants were reviewed and approved by UAB Institutional Review Board. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.
AUTHOR CONTRIBUTIONS AC and TG were responsible for data acquisition and analysis. PL performed all the statistical analyses. MM and FO helped with the approach and interpretation. AS conceived the study and wrote the manuscript. All authors contributed to the article and approved the submitted version.
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
Apicella, Campopiano, Mantuano, Mazoni, Coppelli et al., COVID-19 in people with diabetes: understanding the reasons for worse outcomes, Lancet Diabetes Endocrinol,
doi:10.1016/S2213-8587(20)30238-2Bramante, Ingraham, Murray, Marmor, Hoversten et al., Observational Study of Metformin and Risk of Mortality in Patients Hospitalized with Covid-19, MedRxiv Prepr Server Health Sci,
doi:10.1101/2020.06.19.20135095Burton, Fort, Seoane, Hospitalization and Mortality among Black Patients and White Patients with Covid-19, New Engl J Med,
doi:10.1056/NEJMsa2011686Cai, Chen, Wang, Luo, Liu et al., Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China, Diabetes Care,
doi:10.2337/dc20-0576Cameron, Morrison, Levin, Mohan, Forteath et al., Anti-Inflammatory Effects of Metformin Irrespective of Diabetes Status, Circ Res,
doi:10.1161/CIRCRESAHA.116.308445Cariou, Hadjadj, Wargny, Pichelin, Al-Salameh et al., Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study, Diabetologia,
doi:10.1007/s00125-020-05180-xChen, Zheng, Zhang, Zhang, Wu et al., Clinical characteristics of 145 patients with corona virus disease 2019 (COVID-19) in Taizhou, Infection,
doi:10.1007/s15010-020-01432-5Christiansen, Johansen, Christensen, 'brien, Tonnesen et al., Preadmission metformin use and mortality among intensive care patients with diabetes: a cohort study, Crit Care,
doi:10.1186/cc12886Crouse, Grimes, Li, Might, Ovalle et al., Metformin Use Is Associated with Reduced Mortality in a Diverse Population with Covid-19 and Diabetes, MedRxiv Prepr Server Health Sci,
doi:10.1101/2020.07.29.20164020Golden, Yajnik, Phatak, Hanson, Knowler, Racial/ethnic differences in the burden of type 2 diabetes over the life course: a focus on the USA and India, Diabetologia,
doi:10.1007/s00125-019-4968-0Grant, The effects of metformin on the fibrinolytic system in diabetic and non-diabetic subjects, Diabete Metabol
Hariyanto, Kurniawan, Metformin use is associated with reduced mortality rate from coronavirus disease 2019 (COVID-19) infection, Obes Med,
doi:10.1016/j.obmed.2020.100290Holmes L Jr, Enwere, Williams, Ogundele, Chavan et al., Black-White Risk Differentials in COVID-19 (SARS-COV2) Transmission, Mortality and Case Fatality in the United States: Translational Epidemiologic Perspective and Challenges, Int J Environ Res Public Health,
doi:10.3390/ijerph17124322Li, Wang, Chen, Zuo, Zhang et al., COVID-19 infection may cause ketosis and ketoacidosis, Diabetes Obes Metab,
doi:10.1111/dom.14057Luo, Qiu, Liu, Liu, Zheng et al., Metformin Treatment Was Associated with Decreased Mortality in COVID-19 Patients with Diabetes in a Retrospective Analysis, Am J Trop Med Hygiene,
doi:10.4269/ajtmh.20-0375Mauvais-Jarvis, Aging, Male Sex, Obesity, and Metabolic Inflammation Create the Perfect Storm for COVID-19, Diabetes,
doi:10.2337/dbi19-0023Mugabo, Li, Renier, The connection between C-reactive protein (CRP) and diabetic vasculopathy. Focus on preclinical findings, Curr Diabetes Rev,
doi:10.2174/157339910790442628Nogami, Muraki, Imano, Iso, Risk of disseminated intravascular coagulation in patients with type 2 diabetes mellitus: retrospective cohort study, BMJ Open,
doi:10.1136/bmjopen-2016-013894Palaiodimos, Kokkinidis, Li, Karamanis, Ognibene et al., Severe obesity, increasing age and male sex are independently associated with worse in-hospital outcomes, and higher in-hospital mortality, in a cohort of patients with COVID-19 in the Bronx, New York, Metabol: Clin Experiment,
doi:10.1016/j.metabol.2020.154262Richardson, Hirsch, Narasimhan, Crawford, Mcginn et al., Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area, Jama,
doi:10.1001/jama.2020.6775Scheen, Marre, Thivolet, Prognostic factors in patients with diabetes hospitalized for COVID-19: Findings from the CORONADO study and other recent reports, Diabetes Metab,
doi:10.1016/j.diabet.2020.05.008Tai, Shah, Doubeni, Sia, Wieland, The Disproportionate Impact of COVID-19 on Racial and Ethnic Minorities in the United States, Clin Infect Dis Off Publ Infect Dis Soc A,
doi:10.1093/cid/ciaa815Tan, Alquraini, Mizokami-Stout, Maceachern, Metformin: From Research to Clinical Practice, Endocrinol Metab Clinics North A,
doi:10.1016/j.ecl.2016.06.008Tsoyi, Jang, Nizamutdinova, Kim, Lee et al., Metformin inhibits HMGB1 release in LPS-treated RAW 264.7 cells and increases survival rate of endotoxaemic mice, Br J Pharmacol,
doi:10.1111/j.1476-5381.2010.01126.xWang, Hu, Hu, Zhu, Liu et al., Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China, Jama,
doi:10.1001/jama.2020.1585Xin, Wei, Ji, Zheng, Gu et al., Metformin Uniquely Prevents Thrombosis by Inhibiting Platelet Activation and mtDNA Release, Sci Rep,
doi:10.1038/srep36222Yang, Han, Nilsson-Payant, Gupta, Wang et al., A Human Pluripotent Stem Cell-based Platform to Study SARS-CoV-2 Tropism and Model Virus Infection in Human Cells and Organoids, Cell Stem Cell,
doi:10.1016/j.stem.2020.06.015Zhu, She, Cheng, Qin, Zhang et al., Association of Blood Glucose Control and Outcomes in Patients with COVID-19 and Pre-existing Type 2 Diabetes, Cell Metab,
doi:10.1016/j.cmet.2020.04.021
